Skip to main content
Industry News
Clinical trial underway for Lyme disease vaccine

More than 800 people are participating in a Phase II clinical trial of a Lyme disease vaccine that could be on the market within five years, says Thomas Lingelbach, CEO of developer Valneva. The company is also working on a vaccine for mosquito-borne Chikungunya virus.

Full Story: